

## Patent Docket P1974R1

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Baldwin et al.

Serial No.:10/658,482

Filed: September 9, 2003

For: Novel Composition and Methods for

the Treatement of Immune Related

Disease.

Group Art Unit: 1644

Examiner: Szperka, Michael Edward

Confirmation: 3368

**Customer No.: 09157** 

**CERTIFICATE OF MAILING** 

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Assistant Commissioner of Patentes Washington, D.C. 20231 on

September 20,2005

Teri Lee

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

## RESPONSE TO RESTRICTION REQUIREMENT

In response to the Restriction Requirement dated August 31, 2005, issued in connection with the above application, please consider the following election and remarks.

In response to the outstanding Restriction Requirement, Applicants hereby provisionally elect the invention of Group I, specifically Claims 1-8 drawn to nucleic acids, vectors and host cells comprising SEQ ID NO:1, classified in class 536, subclass 23.5, and class 435, subclass 325. This election is made with without traverse.

The statutory period for reply is one month, therefore making this a timely reply. The Commissioner is authorized to charge any additional fees which may be required, including extension fees, or credit any overpayment to Deposit Account No. 07-0630.

The examiner is invited to contact the undersigned at (650) 225-3733 if any issues may be resolved in that manner.

Respectfully submitted,

GENENTECH, INC.

David A. Carpenter, Ph.D. Reg. No. 45,945

1 DNA Way, MS 49 South San Francisco, CA 94080

Date: September 20, 2005

Phone: (650) 225-3733 Fax: (650) 952-9881 carpenda@gene.com